Mimedx MDXG
- Market cap
- $478.6M
- PE
- n/m
- a loss over the last year
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- 1.6×
- EV/EBIT
- 41.1×
- Revenue, 12 months
- $303.7M
- −23% on a year ago
- Net margin
- −6.3%
- Free cash flow yield
- n/m
- not a meaningful number
Mimedx trades at 1.6× sales. Its trailing earnings are negative, so it has no PE. Revenue was $303.7M over the last twelve months, down 23% on a year earlier with a −6% net margin.
Charts
Financials
| Income statement | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $86.8M+17% | $84.7M+18% | $87.2M+7% | $84.1M+3% | $92.9M+7% | $88.2M+4% | $98.6M+13% | $113.7M+35% | $118.1M+27% | $59M−33% | $64.4M−35% | $62.3M−45% | |
| Cost of revenue | $13.8M−4% | $13M+5% | $14.9M+9% | $15.3M+4% | $16.9M+22% | $16.6M+28% | $18.7M+26% | $18.7M+22% | $19.1M+13% | $17.4M+5% | $20M+7% | $12.6M−33% |
| Gross profit | $73M+22% | $71.7M+21% | $72.4M+7% | $68.7M+3% | $76M+4% | $71.6M−0% | $79.9M+11% | $95M+38% | $99M+30% | $41.6M−42% | $44.4M−45% | $49.7M−48% |
| R&D | $2.4M−55% | $2.8M−19% | $3M−18% | $2.9M−5% | $3.6M+47% | $3.3M+17% | $3.3M+10% | $3.7M+27% | $4.8M+33% | $4.1M+24% | $2.8M−16% | $2.8M−25% |
| SG&A | $54.4M+9% | $55.1M+6% | $55.4M+7% | $53.5M+2% | $61M+12% | $60M+9% | $64.2M+16% | $69M+29% | $73.1M+20% | $53.2M−11% | $59.8M−7% | $58.3M−16% |
| $15.5M+1352% | $13.2M | $23.4M+116% | $11.2M+0% | $11.1M−29% | $8.3M−38% | $12.4M−47% | $22.2M+99% | $21.1M+91% | −$16M | −$18.5M | −$11.7M | |
| Interest expense | n/a | $2.4M+53% | $522K−68% | $521K−69% | $521K | $478K−80% | $475K−9% | $425K−18% | $405K−22% | $402K−16% | n/a | n/a |
| Pre-tax income | $13.9M | $11.4M | $23.2M+153% | $11.4M+21% | $11.2M−19% | $8.6M−25% | $13M−44% | $22.8M+100% | $21.8M+94% | −$15.3M | −$17.8M | −$11.1M |
| −$37.4M | $2.3M+4504% | $5.6M | $3.5M+499% | $3.8M | $1.6M−32% | $3.4M−39% | $6.1M+72% | $6.6M+73% | −$4.5M | −$2.9M | −$2.4M | |
| Net income | $53.5M | $9.3M | $17.6M+1369% | $8.1M−5% | $7.4M−86% | $7M−24% | $9.6M−45% | $16.7M+107% | $15.2M+104% | −$10.9M | −$14.8M | −$8.7M |
| $0.23 | $0.06 | $0.12+1100% | $0.05−17% | $0.05−78% | $0.05−17% | $0.06−50% | $0.11+120% | $0.10+100% | −$0.07 | −$0.10 | −$0.06 | |
| 232.2M+104% | 150M+31% | 148.9M+1% | 148.4M−1% | 149.3M−36% | 149.7M−0% | 149.3M+0% | 149.7M+1% | 150.2M+1% | 148.4M−1% | 147.8M−1% | 145.9M−3% |
Gross profit: 11 periods, Q2 FY10 to Q4 FY12: not printed by the filing, worked out from its own lines.
EPS, diluted: 10 periods, Q4 FY11 to Q4 FY25: quarter's net income to common over its shares, to the cent.
Diluted shares: 7 periods, Q4 FY11 to Q4 FY22: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days. 7 periods, Q4 FY14 to Q4 FY25: share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Instruments & Supplies nearest Mimedx's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| MDXGMimedx | $478.6M | n/m | 21.0× | 1.6× | −23% | −6.3% | |
| TCMDTactile Systems Technology | $518.1M | 21.2× | 62.3× | 1.5× | +17% | 7.1% | |
| EMBCEmbecta | $350.7M | 4.2× | 11.6× | 0.3× | −8% | 8.6% | |
| MOVMovado | $710.9M | 17.7× | 13.4× | 1.0× | +5% | 6.0% | |
| INFUInfuSystem | $275.7M | 33.8× | 43.5× | 1.9× | +2% | 6.0% | |
| IRMDIradimed | $1B | 42.5× | 41.5× | 11.4× | +11% | 26.8% | |
| UTMDUtah Medical Products | $224.6M | 21.5× | 20.9× | 6.2× | −7% | 29.0% | |
| IARTIntegra Lifesciences | $1.1B | 80.1× | 46.3× | 0.6× | +1% | 0.8% | |
| BVSBioventus | $1.1B | 17.1× | 27.1× | 1.9× | +4% | 9.4% | |
| PDEXPro DEX | $184.5M | 15.9× | 16.5× | 2.3× | +13% | 15.1% | |
| STAAStaar Surgical | $1.3B | 356× | 144× | 3.7× | +51% | 1.1% | |
| Peer median | $614.5M | 21.3× | 34.3× | 1.9× | +5% | 7.8% |
More on Mimedx
Each number over time
- PE ratio
- Price to sales ratio
- EV/EBIT
- Price to book ratio
- Market cap
- Revenue
- EPS
- Free cash flow
- Profit margin
- Shares outstanding
Its groups
About
- Industry
- Medical - Instruments & Supplies
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .